ALVAC-CEA-B7.1

AXP000188.1 · Cancer vaccine

Platform
canarypox (ALVAC)
Targets
CEACAM5

Names

NameTypeSource
ALVAC-CEA-B7.1preferred name, codecurator, ncit
ALVAC-B7-CEA ambiguoussynonymncit
ALVAC-CEA (6D)-B7.1 ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
canarypox virus (NCBI Taxonomy 44088)
Strain
ALVAC
Replication
non replicating
Modifications
CEA and CD80 (B7.1) cassettes in the ALVAC canarypox vector
Transgenes
CEACAM5, CD80
Source
evidence

Cross-references

NCI Thesaurus
C1977

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT00027833Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal CancerUnknownPhase 22001-12Colorectal Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 18676757Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2008cited by trial NCT00027833
PMID 11350882The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research2001name in title: ALVAC-CEA-B7.1
PMID 10873071Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research2000name in abstract: ALVAC-CEA-B7.1
PMID 11092617Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.Cancer immunology, immunotherapy : CII2000name in abstract: ALVAC-CEA-B7.1

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 12596363Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.Current opinion in molecular therapeutics2002name in title: ALVAC-CEA-B7.1

Notes

Replication-defective canarypox (ALVAC) vaccine encoding CEA (CEACAM5) with the costimulatory molecule B7.1 (CD80); early-phase NCI trials in CEA-expressing cancers, some with GM-CSF or chemotherapy. NCIt also holds a CEA(6D) epitope-modified variant (C29982) and plain ALVAC-CEA concepts (C1648, C2743); those are recorded as separate names here only where the construct matches. Originator (Virogenetics/Aventis Pasteur) and vCP code not verified in this pass.

How to cite

ALVAC-CEA-B7.1 (AXP000188.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000188.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.